No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial

@inproceedings{Milpied2010NoBO,
  title={No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial},
  author={N. Milpied and Steven Legouill and Thierry Lamy and Vincent Delwail and R{\'e}my Gressin and Denis Guyotat and Gandhi Damaj and Charles Foussard and Philippe Quittet and Herv{\'e} Maisonneuve and Erick Deconinck and François G. Dreyfus and Emmanuel Gyan and Laurent Sutton and Nadine Morineau and Magda Alexis and Fr{\'e}d{\'e}ric Perry and Mathieu Sauvezie},
  year={2010}
}
Abstract 685 Background: In 2004 we have shown that first-line intensive therapy plus transplantation of autologous hematopoietic stem cells lead to an improved EFS and OS over standard CHOP regimen in adults with disseminated aggressive lymphomas (NEJM 2004; 350: 1287). Then the rituximab era came. We have shown that the addition of R to the intensive therapy was feasible and might further improve the results (BBMT 2010; 16: 672). We present here the preliminary analysis of a multicenter… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
VIEW 4 EXCERPTS
CITES RESULTS & METHODS
HIGHLY INFLUENCED

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 1 EXCERPT

Myeloablation for lymphoma--question answered?

  • The New England journal of medicine
  • 2013